Eli Lilly and Company (LLY)
Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?
Eli Lilly and Company LLY has reached a significant support level, making it an attractive option for investors from a technical standpoint. Earlier this week, the stock broke through its 50-day simple moving average (SMA), indicating a potential short-term bullish trend.
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (June 2025)
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%.
Should You Buy Eli Lilly Stock Before June 22?
Eli Lilly (LLY 4.33%) stock hasn't been doing too well this year, but that could change later this month. A couple of key events are on the horizon this month during which the company will release new data from studies relating to multiple GLP-1 drugs.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Rare Outflow Signals Hit Eli Lilly Shares
“Buy low, sell high” is a common investing mantra. It's easy to understand, but often hard to execute because emotion gets in the way.
LLY Stock Too Cheap At $750?
Question: Why would you pay 81 times earnings for AbbVie stock when you can buy LLY for a similar valuation of 76 times earnings? You wouldn't, especially when you consider three simple facts:
Eli Lilly : A Breakout Biotech Powerhouse With Room to Run
Eli Lilly NYSE: LLY has transformed from a steady pharmaceutical giant into one of Wall Street's standout growth stories—and it's not just hype. Powered by blockbuster drugs for diabetes and weight loss, a deep pipeline of next-generation treatments, and aggressive investment in future capacity, Lilly is rewriting what long-term success looks like in Big Pharma.
Novo Nordisk's weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly's Zepbound, and now the company is trying to get back on track
Novo Nordisk's weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly's Zepbound, and now the company is trying to get back on track.
Eli Lilly to Expand Pain Pipeline With $1B SiteOne Buyout Offer
LLY inks $1B deal to acquire SiteOne, adding phase II-ready pain drug STC-004 to strengthen its neuroscience pipeline.
Eli Lilly expands neuroscience pipeline with $1B acquisition of SiteOne therapeutics
Eli Lilly and Co (NYSE:LLY) announced it is acquiring SiteOne Therapeutics, a private biotech firm developing small-molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, for up to $1 billion. This includes the acquisition of STC-004, a Nav1.8 inhibitor being studied for the treatment of pain.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker last week abruptly announced that longtime CEO Lars Fruergaard Jorgensen is stepping down, as its obesity injection Wegovy loses ground to Eli Lilly's rival treatment, Zepbound.
